Theratechnologies Inc T.TH

New Press Release - Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

Data show that sudocetaxel zendusortide (TH1902) can induce tumor infiltrating lymphocytes and potentiate anti-PD-L1 immunotherapy in a melanoma mouse modelTwo other studies highlight activity of TH1902 in SORT1+ triple-negative and HER2+ breast cancers, as well as high expression of SORT1 in...read article.

[Wino115]

It's Alive.... well, sort of. This is pre-clinical again so grain of salt needed. I would point out two things though.  One is that there are now 2 combos they have done that show adding TH1902 to an existing therapy amplifies the good results. There was the carboplatin study and now this one with Anti PD-1L. This is interesting because PD-L1 is in the standard therapy treatment for

[Wino115]

Some info on "Cold Tumors",  basically resistant to immunotherapies which already have low response rates.   Also info on PD-L1 in "cold tumors".  I didn't list sources but they are two papers you can lookup by searching the text.  Maybe they get lucky and a PD-L1 drug company looks to trial the combo to hit cold tumors they currently fail on. Once